Veracyte Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Veracyte, Inc (VCYT) PT Lowered to $54 at Needham & Company
May 11, 2021 6:34 AM EDTNeedham & Company analyst Stephen Unger lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $54.00 (from $88.00) while maintaining a Buy rating.
The analyst commented, "VCYT's 1Q21 revenue was in line with its 4/16/21 preannouncement and EPS adjusted for one-time acquisition expenses beat consensus. Organic... More
Veracyte (VCYT) Tops Q1 EPS by 78c, Revenues Beat
May 10, 2021 4:31 PM EDTVeracyte (NASDAQ: VCYT) reported Q1 EPS of $0.66, $0.78 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $36.7 million versus the consensus estimate of $32.67 million.
Total Revenue was $36.7 million, including $3.8 million for urologic cancer testing, an increase of 18%;Gross Margin was 66%;Operating Expenses were $82.1 million. Operating Expenses, Excluding Cost of Revenue, were $69.7 million, including $35.1 million related to... More